首页> 美国卫生研究院文献>The Journal of Physiology >Nitric oxide is not permissive for cutaneous active vasodilatation in humans
【2h】

Nitric oxide is not permissive for cutaneous active vasodilatation in humans

机译:一氧化氮不允许人类进行皮肤活性血管舒张

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The precise role of nitric oxide (NO) in cutaneous active vasodilatation in humans is unknown. We tested the hypothesis that NO is necessary to permit the action of an unknown vasodilator. Specifically, we investigated whether a low-dose infusion of exogenous NO, in the form of sodium nitroprusside (SNP), would fully restore vasodilatation in an area of skin in which endogenous NO was inhibited during hyperthermia. This finding would suggest a ‘permissive’ role for NO in active vasodilatation. Eight subjects were instrumented with three microdialysis fibres in forearm skin. Sites were randomly assigned to (1) Site A: control site; (2) Site B: NO synthase (NOS) inhibition during established hyperthermia; or (3) Site C: NOS inhibition throughout the protocol. Red blood cell flux was measured using laser-Doppler flowmetry (LDF) and cutaneous vascular conductance (CVC; LDF/mean arterial pressure) was normalized to maximal vasodilatation at each site. In Site B, NG-nitro-l-arginine methyl ester (l-NAME) infusion during hyperthermia reduced CVC by ∼32 % (65 ± 4 % CVCmaxvs. 45 ± 4 % CVCmax; P < 0.05). Vasodilatation was not restored to pre-NOS inhibition values in this site following low-dose SNP infusion (55 ± 4 % CVCmaxvs. 65 ± 4 % CVCmax; P < 0.05). CVC remained significantly lower than the control site with low-dose SNP infusion in Site C (P < 0.05). The rise in CVC with low-dose SNP (ΔCVC) was significantly greater in Site B and Site C during hyperthermia compared to normothermia (P < 0.05). No difference in ΔCVC was observed between hyperthermia and normothermia in the control site (Site A). Thus, NO does not act permissively in cutaneous active vasodilatation in humans but may directly mediate vasodilatation and enhance the effect of an unknown active vasodilator.
机译:一氧化氮(NO)在人类皮肤活动性血管舒张中的确切作用尚不清楚。我们检验了以下假设,即NO必须允许未知的血管扩张药起作用。具体来说,我们调查了低剂量的硝普钠(SNP)形式的外源性NO注入是否会完全恢复在高温期间内源性NO被抑制的皮肤区域的血管舒张。这一发现提示NO在主动血管舒张中起“放任性”作用。八名受试者在前臂皮肤中装有三种微透析纤维。将地点随机分配给(1)地点A:对照地点; (2)B位:确定的高温期间NO合酶(NOS)的抑制;或(3)站点C:在整个实验方案中均抑制NOS。使用激光多普勒血流仪(LDF)测量红细胞通量,并将皮肤血管电导率(CVC; LDF /平均动脉压)标准化为每个部位的最大血管扩张。在部位B中,热疗期间输注N G -硝基-1-精氨酸甲酯(l-NAME)使CVC降低了约32%(65±4%CVCmaxvs。45±4%CVCmax; P < 0.05)。低剂量SNP输注后,该部位的血管舒张功能未恢复到NOS抑制前的水平(55±4%CVCmaxvs。65±4%CVCmax; P <0.05)。在C部位低剂量SNP输注的情况下,CVC仍显着低于对照部位(P <0.05)。与正常体温相比,在体温过高的部位B和部位C中,低剂量SNP(ΔCVC)引起的CVC升高显着更大(P <0.05)。在对照部位(站点A)的高温和正常体温之间未观察到ΔCVC的差异。因此,NO在人的皮肤活动性血管舒张中不是不允许的,而是可以直接介导血管舒张并增强未知活动性血管舒张剂的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号